Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia

Faith B. Dickerson, John J. Boronow, Cassie R. Stallings, Andrea E. Origoni, Robert H. Yolken

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The study was an investigation of the effect of the antiviral medication valacyclovir on the symptoms of outpatients with persistent schizophrenia. Method: Oral valacyclovir, 1 g twice daily, was administered to 65 outpatients over 16 weeks along with their usual psychiatric medications. Changes in psychiatric symptoms were measured with the Positive and Negative Syndrome Scale and were tested for correlations with antibodies to potentially neurotropic human herpesviruses, as measured by immunoassay before the start of the therapy. Results: There was a significant improvement in the psychiatric symptoms of individuals who were seropositive for cytomegalovirus. Improvement was not associated with antibodies to other herpesviruses or to a range of demographic and clinical variables. Conclusions: The replication of cytomegalovirus may contribute to the symptoms of schizophrenia in some individuals.

Original languageEnglish (US)
Pages (from-to)2234-2236
Number of pages3
JournalAmerican Journal of Psychiatry
Volume160
Issue number12
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia'. Together they form a unique fingerprint.

Cite this